VeriChip Corporation (“VeriChip”) (NASDAQ: CHIP) and its development partner RECEPTORS LLC, a technology company whose AFFINITY by DESIGN™ chemistry platform can be applied to the development of selective binding products, announced today that VeriChip plans to fund its existing development partnership with RECEPTORS to launch Phase II development of an in vivo glucose-sensing RFID microchip. In Phase II of this program, which is expected to be completed in the second quarter of 2010, the critical binding environment and competitor agent components of the glucose sensor will be optimized for system stability, sensitivity and specificity.
VeriChip previously announced in November 2008 that RECEPTORS completed Phase I of the project and successfully prepared prototype examples for both the glucose-selective binding environment and the glucose-competitive signaling component. These critical components were used to demonstrate the bench-top format application of the glucose-sensing system to the detection of glucose levels. This demonstration is the proof-of-concept foundation of the glucose-sensing system.
Also in November 2008, VeriChip's Chairman and CEO, Scott R. Silverman, purchased 5.4 million shares of VeriChip common stock from former controlling stockholder Digital Angel Corporation. Simultaneously, in a separate transaction, VeriChip purchased from Digital Angel all patents related to an embedded bio-sensor system for use in humans and the assignment of any rights of Digital Angel under a development agreement associated with the development of the implantable glucose-sensing microchip. These two events positioned the Company to move forward with the development of the in vivo glucose-sensing RFID microchip.